Arima Genomics, Inc ., a company leveraging whole-genome sequence and structure information to provide comprehensive cancer therapy selection insights, today announced new data to be presented at the ...

The Phase II OCULE-01 study in uveal melanoma started in March 2025, the PULMO-01 study in non-small cell lung cancer (NSCLC) started in May 2025 and the HEMA-MED Phase I/II study in myelofibrosis ...

Onctura initiates phase I/II trial of roginolisib in patients with myelofibrosis who are no longer responding to JAK inhibition: Geneva, Switzerland Friday, December 5, 2025, 15: ...

● Conference: ESMO Immuno-Oncology (ESMO-IO) 2025 Annual Congress ● Title: CAPTN-3 unique design demonstrated by 2 novel platform compounds ● Presenter: Dr. Hadas Reuveni ● Presentation Number: FPN# ...

Atavistik Bio to present the discovery and characterization of novel allosteric JAK2 V617F selective inhibitors that suppress mutant-dependent ...

Amnesty International piggybacked on Miami Art Week to unveil its report on Miami’s Krome immigration detention center and Alligator Alcatraz.

You know that feeling when you’re watching a movie and suddenly a car appears on screen that makes you forget about the plot ...

Data demonstrate superior efficacy compared to ruxolitinib, an approved type I JAK2 inhibitor, including reductions in mutant ...

ISC Biology Specimen Paper 2026 Class 12 helps students understand exam pattern, important topics, and marking scheme for the ...

The 24th HUPO World Congress showed a field growing beyond mass spectrometry and starting to think in terms of impact of its ecosystems.

The Mercedes SLR McLaren arrived as more than a fast grand tourer. It was a deliberate attempt to translate the rarefied ...

Mixed chimerism or relapses following TSC-101 infusions were found to be significantly associated with greater ex vivo expansion of TCR-T cells during the manufacturing process. A new commercial-ready ...